Semaglutide Research for Cardiovascular Disease
An evidence-based overview of research examining Semaglutide in the context of cardiovascular disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide has demonstrated cardiovascular protection in multiple large outcome trials. The SELECT trial (N=17,604) showed 20% reduction in major adverse cardiovascular events (MACE: cardiovascular death, heart attack, stroke) in obese individuals with established CVD but without diabetes. The SOUL trial confirmed oral semaglutide provides similar cardiovascular benefit (14% MACE reduction) in type 2 diabetes with high cardiovascular risk. These findings led to FDA approval for cardiovascular risk reduction. The cardioprotective mechanism is not fully understood but likely involves weight loss, improved metabolic parameters, reduced inflammation, and possibly direct effects on cardiovascular tissue. Benefits are seen consistently across patient subgroups including those with heart failure.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Cardiovascular Disease
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.